Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Minerva Med
; 111(5): 395-410, 2020 Oct.
Article
en En
| MEDLINE
| ID: mdl-32955828
ABSTRACT
After being in the therapeutic wilderness for several decades, acute myeloid leukemia has been recently thrust into the limelight with a series of drug approvals. Technical refinements in production, genetic manipulation and chemical modification of monoclonal antibodies led to growing interest in antibodies-based treatment strategies. Much of the focus of these efforts in acute myeloid leukemia has been on CD33 as a target. On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refractory CD33+ acute myeloid leukemia. This signals a new chapter in the long and unusual story of gemtuzumab ozogamicin, which was the first antibody-drug conjugate approved for human use by the Food and Drug Administration. In this review we have analyzed the history of this drug which, among several mishaps, is experiencing a second youth and still represents a field to be further explored.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Leucemia Mieloide Aguda
/
Lectina 3 Similar a Ig de Unión al Ácido Siálico
/
Antineoplásicos Inmunológicos
/
Gemtuzumab
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Animals
/
Humans
/
Middle aged
Idioma:
En
Año:
2020
Tipo del documento:
Article